Rothschild Investment LLC Makes New $81,000 Investment in Insulet Co. (NASDAQ:PODD)

Rothschild Investment LLC purchased a new stake in Insulet Co. (NASDAQ:PODD) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 401 shares of the medical instruments supplier’s stock, valued at approximately $81,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Sunbelt Securities Inc. bought a new position in Insulet in the first quarter valued at $29,000. International Assets Investment Management LLC acquired a new stake in shares of Insulet in the second quarter valued at about $32,000. Benjamin F. Edwards & Company Inc. bought a new stake in Insulet during the fourth quarter worth about $34,000. UMB Bank n.a. boosted its position in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter. Finally, Jones Financial Companies Lllp bought a new position in Insulet in the fourth quarter valued at approximately $40,000.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on PODD shares. Redburn Atlantic started coverage on Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 price objective on the stock. BTIG Research cut their price target on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Jefferies Financial Group boosted their price objective on shares of Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Barclays lifted their price target on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $234.00 price objective on shares of Insulet in a research report on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $225.29.

Insider Activity

In related news, SVP Mark N. Field sold 2,131 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the sale, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Mark N. Field sold 2,131 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the sale, the senior vice president now directly owns 14,375 shares in the company, valued at approximately $2,737,431.25. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Timothy J. Scannell sold 7,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.51, for a total value of $1,333,570.00. Following the completion of the sale, the director now directly owns 35,586 shares in the company, valued at $6,779,488.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,631 shares of company stock worth $2,039,316. 0.47% of the stock is currently owned by corporate insiders.

Insulet Trading Up 2.8 %

Shares of PODD stock opened at $212.51 on Thursday. The stock has a market cap of $14.90 billion, a P/E ratio of 64.40, a price-to-earnings-growth ratio of 3.79 and a beta of 1.21. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $223.56. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. The stock has a 50 day simple moving average of $195.70 and a 200 day simple moving average of $183.93.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.01). The company had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. Insulet’s revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.38 earnings per share. On average, research analysts predict that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.